Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2006

View Archived Issues

VE-465, an Aurora kinase inhibitor, shows promising activity in preclinical tests

Japanese scientists report on the activity of moAb-216

Snapshots of newly reported clinical trials in multiple myeloma

VX-680 active at well-tolerated doses in patients with hematologic malignancies

Decapeptyl four-month formulation studied in phase III trials

Pharminox and Schering-Plough partner to discover anticancer therapies

Novel oral chaperones with potential use in Gaucher's disease

Enrollment complete in phase IIb study of apricitabine

Preclinical data support novel targets for neurodegenerative disorders

Isavuconazole begins phase III trials for invasive systemic fungal infections

Speedel stops phase III study of SPP-301 in diabetic nephropathy over safety

MN-221 begins phase II for status asthmaticus

GSK and Genmab sign worldwide agreement for HuMax-CD20

Phase I progress for prophylactic subunit vaccine to prevent S. aureus infections

Recent patents disclose novel therapeutic agents for neurological disorders

New therapeutic agents for gastrointestinal disorders reported in recent patent literature

BZL-101 demonstrates antitumor activity in breast cancer patients

New therapeutic agents for endocrine-related disorders imparted in recent patent literature

Priority review for Torisel NDA in advanced renal cell carcinoma

Phase I study evaluates Crucell's AdVac-based malaria vaccine

TC-2696 begins phase II trial in acute postoperative pain

TTI-1612 receives U.S. and E.U. orphan drug designations in necrotizing enterocolitis

Albuferon begins first pivotal phase III trial

PML reported in lupus patients receiving Rituxan

Phenoptin demonstrates safety and efficacy in PKU patients

TH-9507 achieves endpoints in HIV-associated lipodystrophy study

European CHMP recommends use of Actos with insulin in type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...